What are the main side effects of BPC-157?

BPC-157 side effects and warning signals include No significant toxicity reported at standard research doses in rodent studies, No genotoxicity or mutagenicity identified in preclinical safety assessments, Possible mild, transient injection site reactions (erythema, swelling), Human safety data is essentially absent - no completed, published human safety trial exists, and Not FDA-approved for any medical condition; classified as a research chemical.

What evidence level is BPC-157?

BPC-157 is rated Level B; the listed research status is Phase 2.

Healing & Recovery / Level B / Phase 2 / Last reviewed 2026-06-01

BPC-157 Evidence Guide

BPC-157 still has the strongest preclinical healing profile of any peptide in this library. The June 2026 update adds human arterial-tissue evidence for nitric-oxide-mediated vasorelaxation, but it does not solve the central limitation: no completed human efficacy trial or approved formulation. For research purposes, it remains the most-studied starting point for tissue repair mechanisms, not a clinically validated therapy.

Our Take

Best for: Tendon & ligament repair, gut healing, post-injury recovery
Evidence grade: Level B
Confidence: Moderate
Starting point: 250mcg subcutaneous, twice daily, 8-12 week cycle

Paid field guide / 20 pages / $10

BPC-157 Field Guide

A plain-English guide to what people try with BPC-157, what the evidence actually says, and what I would do differently now.

Written like a user's experience notes: what people try, what seemed to matter, what I would track next time, and where the evidence is strongest.

Get it for $10 Read the overview

Benefits and Evidence

Tendon & Ligament Healing: Level B, mostly non-human evidence - In a rat Achilles tendon transection model (Staresinic et al., J Orthop Res, 2003), BPC-157 at 10mcg/kg daily (intraperitoneal) produced significantly improved collagen fiber organization, tensile strength, and functional recovery at day 14 vs. saline controls. Similar results at the lower 10ng/kg dose suggest a wide therapeutic window. At least 8 additional tendon/ligament models replicate this basic finding, though all are from the same Zagreb research group.
Gut Health & Protection: Level B, mostly non-human evidence - Over 20 rodent studies document protection of gastric mucosa against diverse insults: indomethacin-induced ulcers, ethanol lesions, cysteamine-induced duodenal ulcers, and acetic acid colitis. A systematic review by Sikiric et al. (Curr Pharm Des, 2013) summarizes this body of work. Crucially, BPC-157 was stable in gastric acid in these studies, making oral administration plausible. No human efficacy data has been published despite a Phase 2 IBD trial registration.
Muscle Recovery: Level C, mostly non-human evidence - Rat crush-injury and transection models show BPC-157 accelerates muscle fiber regeneration and reduces fibrosis formation at injury sites. Effect sizes are consistent across studies but all originate from the same lab. No human muscle recovery data exists.
Bone Healing: Level C, mostly non-human evidence - Rat segmental bone defect and pseudoarthrosis models demonstrate improved bone remodeling with systemic BPC-157 administration. Evidence base is smaller than the tendon/GI literature and methodological details (blinding, histomorphometry protocols) are inconsistently reported.
Neuroprotection: Level C, mostly non-human evidence - Rat models of peripheral nerve crush injury and spinal cord transection show improved recovery with BPC-157. Vukojević et al. (Brain Behav, 2020) demonstrated reduced hippocampal damage after ischemia-reperfusion in rats. The translational relevance to human neurological injury is highly speculative at this stage.

Side Effects and Warnings

No significant toxicity reported at standard research doses in rodent studies
No genotoxicity or mutagenicity identified in preclinical safety assessments
Possible mild, transient injection site reactions (erythema, swelling)
Human safety data is essentially absent - no completed, published human safety trial exists
Not FDA-approved for any medical condition; classified as a research chemical
Virtually all evidence is from a single research group at the University of Zagreb - independent replication is limited
Long-term human safety is completely unknown
May interact with drugs that affect the nitric oxide system or dopaminergic signaling

Research Dosage References

Subcutaneous injection - 200-500 mcg - Once or twice daily - The most common protocol in research contexts, extrapolated from rodent dosing (typically 10mcg/kg in rats). Proximity to the injury site is often used based on preclinical protocols, though systemic dosing also shows effects in animal studies.
Oral - 500-1000 mcg - Once or twice daily - BPC-157 is resistant to proteolytic degradation in gastric juice, supporting oral bioavailability in rodent studies. Preferred route for gut-related applications. Human oral bioavailability has not been formally established.
Intramuscular - 200-500 mcg - Once daily - Used as an alternative to subcutaneous in some research protocols. Comparable systemic exposure expected.

Mechanism of Action

BPC-157 appears to promote healing through at least four overlapping mechanisms, though most evidence is from rodent models and in vitro systems: 1. Angiogenesis via VEGF upregulation: Multiple studies from the Sikiric group show BPC-157 increases VEGF expression at injury sites, promoting formation of new blood vessels that support tissue repair. The angiogenic effect has been documented in both tendon and GI injury models. 2. Nitric oxide (NO) system modulation: BPC-157 interacts with the NO/cGMP signaling pathway. In rat models of NSAID-induced gastric damage, the protective effect was partially blocked by NO inhibitors (L-NAME), suggesting NO generation is mechanistically relevant. This same pathway may contribute to anti-inflammatory effects. 3. Growth hormone receptor and FAK-paxillin pathway: Chang et al. (2014) demonstrated in tendon fibroblasts that BPC-157 increases growth hormone receptor expression and activates the FAK-paxillin signaling cascade, which drives fibroblast migration - a critical early step in tendon repair. 4. Cytoprotection of GI epithelium: BPC-157 protects against a striking range of GI insults in animal models - ethanol, indomethacin, cysteamine, acetic acid - through mechanisms that include reducing pro-inflammatory cytokine release and maintaining mucosal integrity. The compound is stable in gastric acid, which is relevant to its potential oral bioavailability.

Legal Status

BPC-157 is not FDA-approved and is not a controlled substance in the United States. It cannot be legally marketed for human consumption. Available as a research chemical. As of 2024, WADA lists peptide hormones and related substances as a prohibited class, though BPC-157 is not individually named - athletes should check current WADA guidelines with their governing body.

Primary Sources

Tendon healing by BPC 157 in rats: results assessed by electron microscopy and force-velocity tests. J Orthop Res, 2003.
Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (IBD): stable gastric pentadecapeptide BPC 157 as both glioblastoma standard-of-care and IBD standard-of-care. Curr Pharm Des, 2011.
Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules, 2014.
BPC 157 and the healing of various tissues. Adv Exp Med Biol, 2021.
The effect of pentadecapeptide BPC 157 on hippocampal ischemia/reperfusion injuries in rats. Brain Behav, 2020.
Novel cytoprotective mediator, stable gastric pentadecapeptide BPC 157: NO-system relation, dose- and time-dependent cytoprotection/healing, J Physiol Paris.. J Physiol Paris, 2010.
Endothelium-Dependent Nitric Oxide-Mediated Vasorelaxant Effects of BPC 157 in Human Internal Mammary Artery. J Clin Med, 2026.
BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers. Pharmaceutics, 2026.